Inhibiting PD-L1 UFMylation by silencing UFL1 or UFM1, or by the defective UFMylation of PD-L1, stabilized PD-L1 in multiple human and murine cancer cells and undermined antitumor immunity both in vitro and in mice [32]. This evidence concerns the gene UFM1 and cancer.